Metastatic human colonic carcinoma: Molecular imaging with pretargeted SPECT and PET in a mouse model

Radiology

Volumn 246, Issue 2, 2008, Pages 497-507

  Sharkey, Robert M ^a   Karacay, Habibe ^a   Vallabhajosula, Shankar ^b   McBride, William J ^c   Rossi, Edmund A ^d   Chang, Chien Hsing ^c,d   Goldsmith, Stanley J ^b   Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Immunomedics   (United States)

^d IBC Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY I 124; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY I 131; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY IN 111; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY TC 99M; CD22 MONOCLONAL ANTIBODY; FLUORODEOXYGLUCOSE F 18; HAPTEN; HISTAMINE SUCCINYL GLYCINE ANTIBODY; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; TF 2 PEPTIDE TC 99M; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; AUTORADIOGRAPHY; CANCER CELL CULTURE; COLON CARCINOMA; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TARGETING; DRUG UPTAKE; HUMAN; HUMAN CELL; ISOTOPE LABELING; LUNG METASTASIS; METASTASIS; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUDE MOUSE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR LOCALIZATION; ANIMAL; COLON TUMOR; DISEASE MODEL; DRUG DELIVERY SYSTEM; FEMALE; IMAGE ENHANCEMENT; LUNG TUMOR; METHODOLOGY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

ANIMALS; ANTIBODIES, MONOCLONAL; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; IMAGE ENHANCEMENT; LUNG NEOPLASMS; MICE; MICE, NUDE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 37649015466     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2462070229     Document Type: Article

References (29)

1. 18F-FDG imaging: pitfalls and artifacts. J Nucl Med Technol 2005;33:145-155.
2. Kostakoglu L, Hardoff R, Mirtcheva R, Goldsmith SJ. PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. RadioGraphics 2004;24:1411-1431.
3. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004;231:305-332.
4. Esteves FP, Schuster DM, Halkar RK. Gastrointestinal tract malignancies and positron emission tomography: an overview. Semin Nucl Med 2006;36:169-181.
5. Atri M. New technologies and directed agents for applications of cancer imaging. J Clin Oncol 2006;24:3299-3308.
6. Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005;11:2785-2808.
7. Kelloff GJ, Krohn KA, Larson SM, et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 2005;11:7967-7985.
8. Yang DJ, Kim EE, Inoue T. Targeted molecular imaging in oncology. Ann Nucl Med 2006;20:1-11.
9. Subhas N, Patel PV, Pannu HK, Jacene HA, Fishman EK, Wahl RL. Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. RadioGraphics 2005;25:1031-1043.
10. Goldenberg DM, Larson SM. Radioimmunodetection in cancer identification. J Nucl Med 1992;33:803-814.
11. Goldenberg DM, Juweid M, Dunn RM, Sharkey RM. Cancer imaging with radiolabeled antibodies: new advances with technetium-99m-labeled monoclonal antibody Fab′ fragments, especially CEA-Scan and prospects for therapy. J Nucl Med Technol 1997;25:18-23.
12. Kenanova V, Wu AM. Tailoring antibodies for radionuclide delivery. Expert Opin Drug Deliv 2006;3:53-70.
13. Olafsen T, Kenanova VE, Sundaresan G, et al. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res 2005;65:5907-5916.
14. Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 1989;30:1358-1366.
15. Rossi EA, Chang CH, Losman MJ, et al. Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells. Clin Cancer Res 2005;11:7122s-7129s.
16. Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM, Chang CH. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci U S A 2006;103:6841-6846.
17. Sharkey RM, Cardillo TM, Rossi EA, et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 2005;11:1250-1255.
18. 124I-labeled hapten-peptide. J Nucl Med 2006;47:1678-1688.
19. Sharkey RM, Weadock KS, Natale A, et al. Successful radioimmunotherapy for lung metastasis of human colonic cancer in nude mice. J Natl Cancer Inst 1991;83:627-632.
20. Goldenberg DM, Hansen HJ. Carcinoembryonic antigen present in human colonic neoplasms serially propagated in hamsters. Science 1972;175:1117-1118.
21. Sharkey RM, Juweid M, Shevitz J, et al. Evaluation of a complementarity-determining regiongrafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies. Cancer Res 1995;55(23 suppl):5935s-5945s.
22. Sharkey RM, McBride WJ, Karacay H, et al. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res 2003;63:354-363.
23. Leung SO, Goldenberg DM, Dion AS, et al. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. Mol Immunol 1995;32:1413-1427.
24. Sharkey RM, Karacay H, Richel H, et al. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. Clin Cancer Res 2003;9:3897S-3913S.
25. Hughes K, Pinsky CM, Petrelli NJ, et al. Use of carcinoembryonic antigen radioimmunodetection and computed tomography for predicting the resectability of recurrent colorectal cancer. Ann Surg 1997;226:621-631.
26. Cai W, Olafsen T, Zhang X, et al. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J Nucl Med 2007;48:304-310.
27. Tai YC, Ruangma A, Rowland D, et al. Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med 2005;46:455-463.
28. Sharkey RM, Goldenberg DM. Advances in radioimmunotherapy in the age of molecular engineering and pretargeting. Cancer Invest 2006;24:82-97.
29. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006;24:823-834.